Epigenomics AG
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The co…
Medical - Diagnostics & Research
DE, Berlin [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 11.03 | 4.46 | 4.02 | |
| Graham Fair Price | 0.00 | 21.58 | 21.58 | |
| PEG | inf | 0.00 | < 0.005 | |
| Price/Book | 4.32 | -0.06 | -0.07 | |
| Price/Cash Flow | -4.32 | 1.32 | 1.38 | |
| Prices/Earnings | -4.32 | 0.07 | 0.07 | |
| Price/Sales | -4.32 | 7.37 | 7.70 | |
| Price/FCF | -4.32 | 1.32 | 1.38 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 0.00 | 0.90 | 0.90 | |
| Operating Margin | 0.00 | 31.77 | 31.77 | |
| ROA | 0.00 | 0.15 | 0.15 | |
| ROE | -0.23 | -0.23 | 0.00 | |
| ROIC | 0.56 | 0.56 | 0.00 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.00 | 32.40 | inf | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 1.82 | 0.00 | inf | |
| EPS QOQ | 1.71 | 0.00 | inf | |
| FCF QOQ | 1.12 | 0.00 | inf | |
| Revenue QOQ | -0.03 | 0.00 | inf | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Not Interpreted
Fundamentals
Leverage & Liquidity
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 395.46 | 395.46 | 0.00 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 3.07 | 3.07 | 0.00 | |
| Quick Ratio | 8.73 | 8.73 | 0.00 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | -9.39 | -9.39 | 0.00 | |
| Cash | 2.47 | 2.47 | 0.00 | |
| Capex | < 0.005 | < 0.005 | 0.00 | |
| Free Cash Flow | 0.44 | 0.44 | 0.00 | |
| Revenue | 0.08 | 0.08 | 0.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Bad
Fundamentals
Financial Health
06 - Financial Health ·
Bad